Apyx Medical (Apyx Medical) Change In Working Capital : $5.54 Mil (TTM As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Change In Working Capital?

Apyx Medical's change in working capital for the quarter that ended in Dec. 2023 was $2.25 Mil.

Apyx Medical's change in working capital for the fiscal year that ended in Dec. 2023 was $5.54 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Apyx Medical Change In Working Capital Historical Data

The historical data trend for Apyx Medical's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Change In Working Capital Chart

Apyx Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-3.32

-10.25

-1.84

-5.22

5.54

Apyx Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.42	0.16	-3.31	6.45	2.25

Apyx Medical Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.54 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Apyx Medical Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Apyx Medical (Apyx Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

BOV:Germany

Address

5115 Ulmerton Road, Clearwater, FL, USA, 33760

Website

https://apyxmedical.com

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Executives

Todd Hornsby	officer: Executive Vice President	14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine	director	75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb	officer: Chief Financial Officer	5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal	director	5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty	director	1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman	director	5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres	director	86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers	officer: Chief Financial Officer	4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron	director, officer: President
Robert Gershon	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii	officer: Chief CommercializationOfficer	23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson	director	C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz	officer: Vice President of Operations